Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. LHC Group, Inc.
  6. Summary
    LHCG   US50187A1079

LHC GROUP, INC.

(LHCG)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/19/2022 01/20/2022 01/21/2022 01/24/2022 01/25/2022 Date
122.36(c) 122.27(c) 120.23(c) 125.22(c) 118.75(c) Last
210 119 245 420 206 483 264 250 317 407 Volume
-2.28% -0.07% -1.67% +4.15% -5.17% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 2 217 M - -
Net income 2021 141 M - -
Net Debt 2021 286 M - -
P/E ratio 2021 26,9x
Yield 2021 -
Sales 2022 2 478 M - -
Net income 2022 187 M - -
Net Debt 2022 226 M - -
P/E ratio 2022 20,0x
Yield 2022 -
Capitalization 3 761 M 3 761 M -
EV / Sales 2021 1,83x
EV / Sales 2022 1,61x
Nbr of Employees 21 150
Free-Float 81,9%
More Financials
Company
LHC Group, Inc. is a health care provider specializing in the post-acute continuum of care. The Company operates through five segments: home health services, hospice services, home and community-based services, facility-based services primarily offered through its long-term acute care hospitals (LTACHs), and healthcare innovations services (HCI). Its home health service segment offers a range of services, including... 
More about the company
Ratings of LHC Group, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about LHC GROUP, INC.
01/10LHC Group to present at 40th Annual J.P. Morgan Healthcare Conference
PR
2021LHC Group's Board Authorizes $250 Million Share Buyback Plan; Shares Higher
MT
2021LHC : Board of Directors authorizes $250 million share repurchase program - Form 8-K
PU
2021LHC GROUP, INC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021LHC Group Board of Directors authorizes $250 million share repurchase program
PR
2021LHC Group, Inc. announces an Equity Buyback for $250 million worth of its shares.
CI
2021LHC Group, Inc. authorizes a Buyback Plan.
CI
2021LHC Group to present at investor conferences in December
PR
2021SVB Leerink Adjusts LHC Group's Price Target to $151 from $149, Keeps Market Perform Ra..
MT
2021Credit Suisse Adjusts LHC Group's Price Target to $184 from $191, Keeps Outperform Rati..
MT
2021RBC Cuts Price Target on LHC Group to $180 From $192, Maintains Outperform Rating
MT
2021LHC GROUP, INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS..
AQ
2021LHC Group announces third quarter 2021 financial results - Form 8-K
PU
2021LHC GROUP, INC : Results of Operations and Financial Condition, Regulation FD Disclosure, ..
AQ
2021LHC Group, Inc. Raises Earnings Guidance for the Full Year 2021
CI
More news
News in other languages on LHC GROUP, INC.
2021Le conseil d'administration de LHC Group autorise un plan de rachat d'actions de 250 mi..
2021HENKEL-CEO : Initiativen Consumer N-Amerika beginnen sich auszuzahlen
2021UPDATE/Henkel sieht Gewinn 2021 nun am unteren Rand der Spanne
2021AUSBLICK/Bei Henkel stehen Margen, Lieferketten, Portfolio im Fokus
2021AUSBLICK/Bei Henkel stehen Margen, Lieferketten, Portfolio im Fokus
More news
Analyst Recommendations on LHC GROUP, INC.
More recommendations
Chart LHC GROUP, INC.
Duration : Period :
LHC Group, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LHC GROUP, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Last Close Price 118,75 $
Average target price 180,08 $
Spread / Average Target 51,6%
EPS Revisions
Managers and Directors
Keith G. Myers Chairman & Chief Executive Officer
Joshua L. Proffitt President & Chief Operating Officer
Dale G. Mackel Chief Financial Officer, Secretary & Executive VP
Angie M. Begnaud Chief Clinical Officer & Executive Vice President
Benjamin Doga Lead Medical Director
Sector and Competitors